These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 23757315)
1. Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine. Cluzeau T; Mounier N; Karsenti JM; Richez V; Legros L; Gastaud L; Garnier G; Re D; Montagne N; Gutnecht J; Gabriel Fuzibet J; Auberger P; Raynaud S; Cassuto JP Am J Hematol; 2013 Sep; 88(9):780-3. PubMed ID: 23757315 [TBL] [Abstract][Full Text] [Related]
2. IPSS-R in 555 Taiwanese patients with primary MDS: Integration of monosomal karyotype can better risk-stratify the patients. Yang YT; Hou HA; Liu CY; Lin CC; Chou WC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Kuo YY; Huang SY; Ko BS; Chen CY; Hsu SC; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF Am J Hematol; 2014 Sep; 89(9):E142-9. PubMed ID: 24845799 [TBL] [Abstract][Full Text] [Related]
3. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. Papageorgiou SG; Vasilatou D; Kontos CK; Kotsianidis I; Symeonidis A; Galanopoulos AG; Hatzimichael E; Megalakaki A; Poulakidas E; Diamantopoulos P; Vassilakopoulos TP; Zikos P; Papadaki H; Mparmparousi D; Bouronikou E; Panayiotidis P; Viniou NA; Pappa V Am J Hematol; 2018 Jul; 93(7):895-901. PubMed ID: 29659040 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762 [TBL] [Abstract][Full Text] [Related]
6. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes]. Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954 [TBL] [Abstract][Full Text] [Related]
7. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine. Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368 [TBL] [Abstract][Full Text] [Related]
8. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938 [TBL] [Abstract][Full Text] [Related]
9. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). Bally C; Thépot S; Quesnel B; Vey N; Dreyfus F; Fadlallah J; Turlure P; de Botton S; Dartigeas C; de Renzis B; Itzykson R; Fenaux P; Adès L Leuk Res; 2013 Jun; 37(6):637-40. PubMed ID: 23499498 [TBL] [Abstract][Full Text] [Related]
10. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Lübbert M; Suciu S; Hagemeijer A; Rüter B; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Muus P; Pflüger KH; Schaefer HE; Bogatyreva L; Aul C; de Witte T; Ganser A; Becker H; Huls G; van der Helm L; Vellenga E; Baron F; Marie JP; Wijermans PW; Ann Hematol; 2016 Jan; 95(2):191-9. PubMed ID: 26596971 [TBL] [Abstract][Full Text] [Related]
11. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697 [TBL] [Abstract][Full Text] [Related]
12. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. Valcárcel D; Ademà V; Solé F; Ortega M; Nomdedeu B; Sanz G; Luño E; Cañizo C; de la Serna J; Ardanaz M; Marco V; Collado R; Grau J; Montoro J; Mallo M; Vallespí T J Clin Oncol; 2013 Mar; 31(7):916-22. PubMed ID: 23319689 [TBL] [Abstract][Full Text] [Related]
13. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. Breems DA; Van Putten WL; De Greef GE; Van Zelderen-Bhola SL; Gerssen-Schoorl KB; Mellink CH; Nieuwint A; Jotterand M; Hagemeijer A; Beverloo HB; Löwenberg B J Clin Oncol; 2008 Oct; 26(29):4791-7. PubMed ID: 18695255 [TBL] [Abstract][Full Text] [Related]
14. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. Vidal V; Robert G; Goursaud L; Durand L; Ginet C; Karsenti JM; Luciano F; Gastaud L; Garnier G; Braun T; Hirsch P; Raffoux E; Nloga AM; Padua RA; Dombret H; Rohrlich P; Ades L; Chomienne C; Auberger P; Fenaux P; Cluzeau T Oncotarget; 2017 Jul; 8(29):47103-47109. PubMed ID: 28514758 [TBL] [Abstract][Full Text] [Related]
15. Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia. van Gelder M; de Wreede LC; Schetelig J; van Biezen A; Volin L; Maertens J; Robin M; Petersen E; de Witte T; Kröger N; Leukemia; 2013 Apr; 27(4):879-88. PubMed ID: 23164802 [TBL] [Abstract][Full Text] [Related]
16. Outcome of allogeneic stem cell transplantation in myelodysplastic syndrome patients: prognostic implication of monosomal karyotype. Wudhikarn K; Van Rheeden R; Leopold C; Rattanaumpawan P; Gingrich R; de Magalhaes Silverman M Eur J Haematol; 2012 Oct; 89(4):294-301. PubMed ID: 22762733 [TBL] [Abstract][Full Text] [Related]
17. Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients. Belli CB; Bengió R; Aranguren PN; Sakamoto F; Flores MG; Watman N; Nucifora E; Prates MV; Arbelbide J; Larripa I Am J Hematol; 2011 Jul; 86(7):540-5. PubMed ID: 21674572 [TBL] [Abstract][Full Text] [Related]
18. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity. Ahn HK; Jang JH; Kim K; Kim HJ; Kim SH; Jung CW; Kim DH Am J Hematol; 2012 Jan; 87(1):37-41. PubMed ID: 22120708 [TBL] [Abstract][Full Text] [Related]
19. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806 [TBL] [Abstract][Full Text] [Related]
20. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]